Christoph Tinchon

Leoben, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Journal: American journal of hematology

Published: August 25, 2023

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.

Journal: Cancers

Published: January 24, 2023

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.

Journal: ESMO open

Published: September 22, 2022

Early cerebrospinal fluid infiltration in TP53-mutated blastic plasmacytoid dendritic cell neoplasm.

Early cerebrospinal fluid infiltration in TP53-mutated blastic plasmacytoid dendritic cell neoplasm.

Journal: Annals of hematology

Published: September 20, 2022

Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.

Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.

Journal: Medical mycology

Published: April 04, 2022

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Journal: Cancers

Published: April 02, 2022

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.

Journal: Breast cancer research : BCR

Published: July 20, 2021

Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.

Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.

Journal: Annals of hematology

Published: June 01, 2021

Concomitant immune thrombocytopenia and bone marrow hemophagocytosis in a patient with SARS-CoV-2.

Concomitant immune thrombocytopenia and bone marrow hemophagocytosis in a patient with SARS-CoV-2.

Journal: Clinical chemistry and laboratory medicine

Published: February 05, 2021

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 169: A 32-year-old woman with anemia in pregnancy.

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 169: A 32-year-old woman with anemia in pregnancy.

Journal: Wiener klinische Wochenschrift

Published: May 03, 2020

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.

Journal: British journal of cancer

Published: April 26, 2020

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 04, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026